Serina Therapeutics, Inc.SERNYSE
Loading
Cash Flow Under PressureContracting
Percentile Rank11
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-16.53M
↓ 96% vs avg
Percentile
P11
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-8.44M
Historical baseline
PeriodValueYoY Change
TTM$-16.53M+3.7%
2024$-17.16M-475.8%
2023$-2.98M-42.9%
2022$-2.09M+11.6%
2021$-2.36M+69.9%
2020$-7.84M+27.4%
2019$-10.80M-9.2%
2018$-9.89M-57.3%
2017$-6.29M+25.6%
2016$-8.45M-